141 related articles for article (PubMed ID: 28919793)
21. Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis.
Geale K; Saridogan E; Lehmann M; Arriagada P; Hultberg M; Henriksson M
Clinicoecon Outcomes Res; 2017; 9():669-676. PubMed ID: 29138584
[TBL] [Abstract][Full Text] [Related]
22. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
23. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
Talaulikar VS; Manyonda IT
Adv Ther; 2012 Aug; 29(8):655-63. PubMed ID: 22903240
[TBL] [Abstract][Full Text] [Related]
24. The economic impact of uterine fibroids in the United States: a summary of published estimates.
Mauskopf J; Flynn M; Thieda P; Spalding J; Duchane J
J Womens Health (Larchmt); 2005 Oct; 14(8):692-703. PubMed ID: 16232101
[TBL] [Abstract][Full Text] [Related]
25. [Effect of GnRH analogues pre-treatment on myomectomy outcomes in reproductive age women].
Hudecek R; Ivanová Z; Smerdová M; Pánková S; Krajcovicová R
Ceska Gynekol; 2012 Apr; 77(2):109-17. PubMed ID: 22702067
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
27. [Meta-analysis of the Italian studies on short-term effects of air pollution].
Biggeri A; Bellini P; Terracini B;
Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
[TBL] [Abstract][Full Text] [Related]
28. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey.
Soliman AM; Margolis MK; Castelli-Haley J; Fuldeore MJ; Owens CD; Coyne KS
Curr Med Res Opin; 2017 Nov; 33(11):1971-1978. PubMed ID: 28836862
[TBL] [Abstract][Full Text] [Related]
29. EMAS position statement: management of uterine fibroids.
Pérez-López FR; Ornat L; Ceausu I; Depypere H; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M;
Maturitas; 2014 Sep; 79(1):106-16. PubMed ID: 24975954
[TBL] [Abstract][Full Text] [Related]
30. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Lee MJ; Yun BS; Seong SJ; Kim ML; Jung YW; Kim MK; Bae HS; Kim DH; Hwang JY
Obstet Gynecol Sci; 2017 Jan; 60(1):69-73. PubMed ID: 28217674
[TBL] [Abstract][Full Text] [Related]
31. Psychometric validation of the 1-month recall Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL).
Coyne KS; Harrington A; Currie BM; Chen J; Gillard P; Spies JB
J Patient Rep Outcomes; 2019 Aug; 3(1):57. PubMed ID: 31444600
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
33. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding.
Tan YH; Lethaby A
Cochrane Database Syst Rev; 2013 Nov; (11):CD010241. PubMed ID: 24234875
[TBL] [Abstract][Full Text] [Related]
34. Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid.
Oderda G; Asche C; Jones KP; Merrill RM; Spalding J
Arch Gynecol Obstet; 2007 Sep; 276(3):211-8. PubMed ID: 17342498
[TBL] [Abstract][Full Text] [Related]
35. Uterine artery embolization as a treatment option for uterine myomas.
Marshburn PB; Matthews ML; Hurst BS
Obstet Gynecol Clin North Am; 2006 Mar; 33(1):125-44. PubMed ID: 16504811
[TBL] [Abstract][Full Text] [Related]
36. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
37. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.
Neri M; Melis GB; Giancane E; Vallerino V; Pilloni M; Piras B; Loddo A; Paoletti AM; Mais V
Int J Womens Health; 2019; 11():535-546. PubMed ID: 31695514
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review.
Lethaby A; Vollenhoven B; Sowter M
BJOG; 2002 Oct; 109(10):1097-108. PubMed ID: 12387461
[TBL] [Abstract][Full Text] [Related]
39. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
Seitz C; Bumbuliene Ž; Costa AR; Heikinheimo O; Heweker A; Hudeček R; Jacquemyn Y; Melis GB; Parashar P; Rechberger T; Sánchez AC; van Aken B; Zatik J; Gemzell-Danielsson K
Contemp Clin Trials; 2017 Apr; 55():56-62. PubMed ID: 28185997
[TBL] [Abstract][Full Text] [Related]
40. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
